Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations

Jennifer E Amengual, MD, Maximilian Lombardo, Kelly M Zullo, Paul M. Johannet, BA, Sathyen A Prabhu, Gonzalez Yulissa, Luigi Scotto, PhD, Ying Wei, Jimmy Duong, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 3708.

https://doi.org/10.1182/blood.V126.23.3708.3708

Published: 2015

Journal Articles

Development and Characterization of Two Lymphoma Cell Lines Resistant to the Selective HDAC6 Inhibitor Ricolinostat (ACY-1215) As a Tool to Better Understand the Biology of HDACs on Lymphoma

Jennifer E Amengual, MD, Paul M. Johannet, BA, Kelly Zullo, MS, Maximilian Lombardo, MS, Owen A. O'Connor, MD PhD

Blood (2014) 124 (21): 1777.

https://doi.org/10.1182/blood.V124.21.1777.1777

Published: 2014

Journal Articles

Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models Of Lymphoma

Jennifer E. Amengual, MD, Paul M Johannet, Xavier Jirau-Serrano, BS, Kelly Zullo, BS, Daniela Hoehn, MD, PhD, Govind Bhagat, MD, Maximilian Lombardo, B.S., Luigi Scotto, PhD, Simon S Jones, PhD, Owen A. O'Connor, MD, PhD

Blood (2013) 122 (21): 648.

https://doi.org/10.1182/blood.V122.21.648.648

Published: 2013

Journal Articles

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor Rocilinostat (ACY-1215) and Bortezomib, Demonstrates Synergistic Antitumor Activity in Preclinical Models of Lymphoma

Jennifer E Amengual, MD, Paul M Johannet, Simon S Jones, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 1650.

https://doi.org/10.1182/blood.V120.21.1650.1650

Published: 2012

Journal Articles

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Jennifer E Amengual, MD, Sean Clark-Garvey, Matko Kalac, MD, PhD, Luigi Scotto, PhD, Enrica Marchi, MD, PhD, Celests Rojas, Ellen Neylon, FNP, MSN, RN, OCN, Paul M Johannet, Salvia Jain, MD, Jasmine M. Zain, MD, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 2725.

https://doi.org/10.1182/blood.V120.21.2725.2725

Published: 2012

NARROW

Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations

Development and Characterization of Two Lymphoma Cell Lines Resistant to the Selective HDAC6 Inhibitor Ricolinostat (ACY-1215) As a Tool to Better Understand the Biology of HDACs on Lymphoma

Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models Of Lymphoma

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor Rocilinostat (ACY-1215) and Bortezomib, Demonstrates Synergistic Antitumor Activity in Preclinical Models of Lymphoma

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Email alerts

ASH Publications

American Society of Hematology

Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations

Development and Characterization of Two Lymphoma Cell Lines Resistant to the Selective HDAC6 Inhibitor Ricolinostat (ACY-1215) As a Tool to Better Understand the Biology of HDACs on Lymphoma

Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models Of Lymphoma

Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor Rocilinostat (ACY-1215) and Bortezomib, Demonstrates Synergistic Antitumor Activity in Preclinical Models of Lymphoma

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only